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In atherosclerotic plaques, the risk of rupture is increased at sites of
macrophage accumulation. Activated macrophages express folate
receptor-β (FR-β), which can be targeted by folate coupled to radioac-
tive ligands to visualize vulnerability. The aim of this study was to ex-
plore the presence of activated macrophages in human atherosclerotic
plaques by 99mTc-folate imaging and to evaluate whether this technique
can discriminate between an M1-like and M2-like macrophage pheno-
type.Methods: Carotid endarterectomy specimens of 20 patients were
incubated with 99mTc-folate, imaged using micro-SPECT, and divided
into 3-mm slices. The mean accumulation was calculated per slice, and
the distribution of M1-like and M2-like macrophages per slice was
quantified by immunohistochemical staining for CD86 as well as induc-
ible nitric oxide synthase (iNOS) for M1 and CD163 and FR-β for M2
macrophages. Monocytes from healthy donors were differentiated to-
wardM1-like or M2-like phenotype by in vitro culturing. Messenger RNA
levels of specific M1 and M2 markers were measured by reverse-
transcription polymerase chain reaction and expression of FR-β,
CD86, and CD163 by flow cytometry. Results: There was a heteroge-
neous accumulation of 99mTc-folate in plaques (median, 2.45 [0.77–
6.40] MBq/g). Slices with the highest 99mTc-folate accumulation of each
plaque showed significantly more expression of FR-β and CD163, com-
pared with slices with the lowest 99mTc-folate accumulation, which
showed significantly more expression of iNOS. In in vitro polarized
macrophages, messenger RNA expression of FR-β, mannose receptor,
IL-10, andmatrix metalloproteinase-9 was significantly increased in M2-
like macrophages, compared with M1-like macrophages. On a receptor
level, CD86 was shown to be overexpressed on M1-like macrophages
whereas FR-β and CD163 were overexpressed on M2-like macro-
phages measured by flow cytometry. Conclusion: Higher numbers of
M2-like macrophages were present in areas of high 99mTc-folate accu-
mulation than areas with low accumulation. It is anticipated that 99mTc-
folate imaging using SPECT as a marker for M2-like macrophages in
atherosclerosis might be a good indicator for plaque vulnerability.
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Cardiovascular atherosclerotic disease is the main cause of
death in the Western world (1). Clinical events such as myocardial
infarction and ischemic cerebrovascular accident are directly related
to the risk of atherosclerotic plaque rupture. Histologic analysis of
a vulnerable plaque suggests the importance of necrotic core size;
extent of inflammation; and angiogenesis, lipid accumulation, and
fibrous cap thickness (2). Furthermore, in plaque vulnerability ma-
trix metalloproteinases (MMPs), reactive oxygen species, inflam-
matory cytokines, and various growth factors released by activated
macrophages play important roles (3). Patients with symptoms and
carotid artery stenosis greater than 70% or those asymptomatic
with carotid artery stenosis of 80%–90% are deemed suitable for
endarterectomy, thereby significantly reducing the risk of subse-
quent major cerebrovascular accident or death (4). Imaging tech-
niques currently used to visualize carotid artery stenosis include
duplex ultrasound, CT angiography, and angiography (5). However,
these techniques focus on anatomic features of the plaque and
barely give any information on molecular and cellular processes.
They therefore cannot distinguish between stable and unstable
plaques. Because plaque composition rather than stenosis is im-
portant in detecting an unstable plaque, new imaging modalities
are needed (5).
18F-FDG PET can be used to identify vulnerable plaques in
atherosclerotic disease, because 18F-FDG accumulates in activated
macrophages. 18F-FDG micro-PET accumulation correlated well
with macrophage content in a rabbit model, whereas in vivo quan-
tification did not support this finding, possibly because of high
accumulation in surrounding tissue (6). Folate receptor-b (FR-b)
is present on activated macrophages but not on resting macro-
phages or other immune cells. For that reason, it might be a good
indicator for inflammation in the human atherosclerotic carotid
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plaque, as previously shown by imaging carotid artery specimens with
fluorescence-labeled folate (7). Furthermore, Ayala-López et al. local-
ized activated macrophages in apolipoprotein E (ApoE) knockout (KO)
mice fed a western diet using a 99mTc-folate–labeled compound (8).
A heterogeneous population of macrophages exists including
a classically activated macrophage type (M1) as well as an
alternatively activated macrophage population (M2) (9). The M1
macrophage is thought to have proinflammatory properties, and po-
larization in vitro is driven by interferon g and low-concentration
lipopolysaccharide. Macrophages are driven toward the M2 type
when the environment includes IL-4 and IL-10 (10). However,
polarization of macrophages within a plaque is determined by the
local microenvironment present in the atherosclerotic lesion and
is thought to be rather more complex than the often used M1/
M2 paradigm (11). As MMPs trigger plaque rupture, a M2-like
macrophage type might be important as a direct cause of plaque
vulnerability by producing tissue degrading MMPs (12).
Therefore, the major goal of this pilot study was to explore the
distribution of macrophage subtypes in atherosclerotic plaques and
the FR-b expression on the respective macrophage subtypes. In
addition, the potential of technetium-labeled folate as a marker for
atherosclerotic carotid plaque vulnerability was explored. To achieve
this goal, the 99mTc-folate signal was compared with FR-b staining
using specimens with a positive imaging ratio (accumulation slice/
total plaque accumulation . 1) to validate the folate–technetium
compound. Additionally, macrophages were differentiated and po-
larized in vitro into M1-like and M2-like macrophages to investi-
gate expression of FR-b and known M1 and M2 markers.
MATERIALS AND METHODS
Study Design
Between August 2011 and May 2012, 20 carotid specimens were
obtained by means of carotid endarterectomy of the carotid bifurcation
using standard techniques (13). Patients underwent open carotid surgery
at the University Medical Center Groningen and were symptomatic
(i.e., with a history of recent cerebrovascular accident, transient ische-
mic attack, or amaurosis fugax). They presented with a stenosis of the
common carotid artery of 70%–99% as detected by duplex ultrasound.
Additionally, asymptomatic patients with a stenosis of 80%–99%, found
by routine control, were eligible for surgical treatment. Risk factors such
as hyperlipidemia, hypertension, smoking status, obesity (body mass index),
and diabetes mellitus were recorded. Hyperlipidemia and hypertension
were defined as described before by our group (7). For validation of
macrophage markers, 6 healthy volunteers were included without known
cardiovascular disease or risk factors. The study was approved by the
Institutional Review Board of the University Medical Center Groningen,
and informed consent was obtained from all patients and healthy volunteers.
Carotid Endarterectomy Sample Collection and Time Path
of Study
The carotid samples collected during carotid endarterectomy were
immediately transported in a phosphate buffer on ice to the U-SPECT-II
system (MILabs), with a mean transport time of 186 6 min. The optimal
incubation time and concentration of 99mTc-folate was determined. To
validate the 99mTc-folate signal, immunohistochemistry was used for
determining M1-like and M2-like macrophage levels in regions with
high and low 99mTc-folate accumulation.
99mTc-Folate Labeling and Imaging of Plaque Using
micro-SPECT
To determine the exact location in which the 99mTc-folate accumula-
tion had taken place within the plaque, ex vivo imaging was performed.
A 99mTc-labeled imaging agent consisting of the vitamin folic acid
conjugated to a chelating agent with specificity for 99mTc was used as
follows: 1 mL of sodium pertechnetate 99mTc injection (100 MBq)
was injected into a shielded vial. The vial was gently swirled for 30 s
to dissolve the lyophilized powder and placed into a lead shield and
incubated at 100C for 18 min. Subsequently, the 99mTc-folate vial
was cooled for 15 min protected from light, and the radiochemical
TABLE 1
Baseline Characteristics and Risk Factors for
Atherosclerosis
Characteristic Patients (n 5 20)
Men (%) 12 (60)
Age (y) 68 ± 8
Symptomatic (%) 18 (90)
Transient ischemic attack (%) 8 (40)
Cerebrovascular accident (%) 7 (35)
Amaurosis fugax (%) 3 (15)
Body mass index (kg/m2) 27 ± 4
Smoking status (%) 10 (50)
.1 pack a day (%) 4 (20)
#1 pack a day (%) 6 (30)
None, smoked in last 10 y (%) 3 (15)
Hypertension (%) 15 (75)
Controlled with single drug (%) 6 (30)
Controlled with 2 drugs, n (%) 5 (25)
Requires . 2 drugs or uncontrolled (%) 4 (20)
Systolic blood pressure (mm Hg) 138 ± 15
Diastolic blood pressure (mm Hg) 74 ± 8
Hyperlipidemia (%) 12 (60)
Use of lipid-lowering drugs (%) 17 (85)
Diabetes mellitus (%) 3 (15)*
*Two patients had diabetes controlled by diet or oral agents,
and 1 patient was on insulin.
Data are mean ± SD, with percentages in parentheses.
FIGURE 1. Transversal (left), coronal (middle), and sagittal (right) sec-
tions of micro-SPECT image of atherosclerotic carotid plaque specimen
after 99mTc-folate incubation showing heterogeneous accumulation.
Transversal image shows that area of higher accumulation (red) is con-
fined within vessel wall.
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purity of 99mTc-folate was determined by instant thin-layer chroma-
tography using saline as the eluent. The radiochemical purity must
be greater than 90% to pass acceptance criteria. The carotid speci-
mens were weighed and incubated for 1 h in 5 mL of a 99mTc-folate–
containing solution at room temperature. After washing, 99mTc-folate
accumulation was measured using the dose calibrator. The specimens
were put into a micro-SPECT scanner, near the center of field of view,
and scanned for 1 h (as determined by serial dilution). micro-SPECT
images were corrected for scatter and reconstructed, applying an
interactive reconstruction algorithm (2-dimensional ordered-subset
expectation maximization). After incubation and scanning, all speci-
mens were divided in equal slices of 3 mm. For every slice, the mean
accumulation was calculated as counts/voxel of region of interest
versus total dose calibrator activity per gram (total plaque weight),




After determining 99mTc-folate accumula-
tion of every slice, slices of plaques of 10 pa-
tients were embedded in paraffin, and sections
of 4 mm were made. Macrophages were iden-
tified by incubation with monoclonal mouse
antihuman CD68 (1:50; mo876 clone PG-M1;
DAKO). For detection of M1 macrophages,
rabbit antihuman inducible nitric oxide syn-
thase (iNOS) and rabbit antihuman antibody
CD86 (ab15323 and ab53004, respectively;
Abcam) were used. To show M2-like macro-
phage distribution, mouse antihuman CD163
(a widely used M2 macrophage marker and
mainly found in advanced human lesions near
intraplaque hemorrhage areas (15); ab74604,
[Abcam]) and biotinylated sheep antihuman
FR-b antibody were used (BAF 5697; R&D
Systems). Also, FR-b and CD163 were used
for double staining to show colocalization of
M2-like macrophages and FR-b expression.
Appropriate secondary antibodies labeled
with horseradish peroxidase and alkaline
phosphatase for double staining were used.
Color reaction was developed using 3, 39-
diaminobenzidine (DAKO) staining with
chromogen (fast red [Sigma] for double stain-
ing with alkaline phosphatase), and sections
were counterstained with hematoxylin. All
sections were stored digitally after examina-
tion using a Nanozoomer Digital Pathology
Scanner (NDP Scan U10074-01; Hamama-
tsu Photonics K.K.) and quantified (percent-
age of positive cells/total cells) with ImageScope
Viewer software (V11.2.0.780 Aperio;
e-Pathology Solution). For validation, slices
with the lowest mean accumulation of the
99mTc-folate signal in imaging were com-
pared with the slices with the highest mean
accumulation in every carotid plaque sepa-
rately (both compared with mean accumula-
tion in the total plaque in counts/voxel).
In Vitro Differentiation and
Polarization of M1-Like and
M2-Like Macrophages
Peripheral blood mononuclear cells were
isolated from 6 healthy donors by density gradient centrifugation using
Lymphoprep (Axis Shield PoC As). Subsequently, monocytes were
allowed to adhere to culture plates. The adherent cells were
maintained for 5 d in RPMI 1640 medium (Lonza) supplemented with
10% filtered fetal calf serum. Macrophage colony-stimulating factor
(20 ng/mL; R&D Systems) was added to the cell culture for differen-
tiation into macrophages. Macrophages were directed toward M1-like
and M2-like phenotypes by use of 48-h stimulation with interferon g
(100 U/mL; PeproTech) and lipopolysaccharide (1 ng/mL; Sigma) or
IL-4 (20 ng/mL) and IL-10 (10 ng/mL) (PeproTech).
Flow Cytometry of M1-Like and M2-Like Macrophages
In vitro–differentiated M1-like and M2-like macrophages were
stained with biotinylated antihuman FR-b antibody (R&D Systems)
to explore protein expression. Streptavidine–allophycocyanine
(Biolegend) was used as a secondary antibody. Anti-CD86-FITC
FIGURE 2. Immunohistochemical staining of 10 atherosclerotic plaques. (A) Staining of CD68,
CD86, CD163, FR-β, and iNOS is depicted in slice with highest accumulation of 99mTc-folate in
plaque. (B) Positive 99mTc-folate slices (accumulation slice/accumulation total plaque . 1) showed
positive correlation with FR-β staining (r 5 0.46, P 5 0.006).
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(fluorescein isothiocyanate) (BD Bioscience) and anti-CD163-PE
(phycoerythrin) (Biolegend) were used to distinguish expression
of these markers on macrophage subtypes. These were measured
using flow cytometry.
RNA Isolation, Complementary DNA Synthesis, and
Quantitative Reverse-Transcription Polymerase
Chain Reaction
RNA was extracted from M1-like and M2-like macrophages as
described before (7). For measurement of messenger RNA (mRNA),
1 mL of a complementary DNA sample was added in duplicate for
amplification by the Taqman real-time PCR system (ABI Prism
7900HT Sequence Detection system; Applied Biosystems). Inves-
tigated genes were glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), IL-6, tumor necrosis factor (TNF), Tolllike receptor
(TLR) 2 and 4, FR-b (folate receptor 2 or b), mannose receptor
(CD206 or MR), IL-10, and MMP-9. Ct (threshold cycle) values
were determined using the software program SDS 2.4 (Applied
Biosystems). Relative gene expression was normalized to the ex-
pression of GAPDH and calculated by the following formula: rela-
tive gene expression 5 2 –DCt (DCt 5 Ct gene of interest – Ct
GAPDH).
Statistics
Values are presented as mean 6 SD or median (with range in
parentheses), unless stated otherwise. For correlations, Pearson and
Spearman correlation coefficients were used when appropriate. A
2-tailed, paired Student t test was used for parametric distributions.
Nonpaired continuous variables with a nonparametric distribution
were analyzed using the Mann–Whitney U test. A 2-sided P value
of less than 0.05 was considered statistically significant. Statistical
tests were done with the Statistical Package for the Social Sciences
(SPSS statistics version 20.0; SPSS Inc.).
RESULTS
Patient Characteristics
Twelve men and 8 women (mean age 6 SD, 68.06 8.4 y) were
included. Patient characteristics are shown in Table 1.
Imaging of Plaque Using micro-SPECT
Imaging of 20 atherosclerotic plaques using micro-SPECT
showed that 99mTc-folate accumulation occurred in specific
areas of the plaques, with a median total activity of 2.45
(range, 0.77–6.40) MBq/g measured in a dose calibrator (Fig.
1). After scanning, all specimens were divided in equal slices, and
ratio per slice was calculated (accumulation slice/total plaque accu-
mulation). There were 5 6 1 slices per atherosclerotic carotid
plaque. 99mTc-folate accumulation was heterogeneously distributed
throughout plaques (slices with highest 99mTc-folate ratio, 1.28
[1.03–2.24], and slices with the lowest 99mTc-folate ratio, 0.8
[0.18–0.99]).
Immunohistochemistry and Validation of 99mTc-Folate Signal
Plaque slices of 10 patients were stained using FR-b to validate
the 99mTc-folate signal and also for CD68 (pan macrophages),
CD86 and iNOS (M1 macrophage markers), and CD163 (M2
macrophage marker). In Figure 2A, representative staining is
shown. All stainings were quantified with ImageScope software
and expressed as percentage of positive cells per total cells. Slices
with a positive 99mTc-folate imaging ratio (accumulation slice/
total plaque accumulation . 1) were positively correlated to
FR-b staining (P 5 0.006, Fig. 2B). Figure 3 shows that FR-b
staining in slices with the highest 99mTc-folate accumulation of
each plaque was higher than in slices with the lowest accumulation
(P5 0.042). The same was shown for CD163 staining (P5 0.036).
FIGURE 3. (A) Quantification of stainings. (A) Slices with highest 99mTc-folate accumulation (closed dots) showed significantly more FR-β expres-
sion than slices with lowest 99mTc-folate accumulation (open dots, P 5 0.043) (left), slices with highest 99mTc-folate accumulation (closed dots)
showed significantly more CD163 staining than slices with lowest 99mTc-folate accumulation (open dots, P 5 0.036) (middle), and slices with lowest
99mTc-folate accumulation (open dots) showed significantly more iNOS staining than slices with highest 99mTc-folate accumulation (closed dots,
P 5 0.043) (right). (B) Double staining of CD163 and FR-β to show colocalization of M2-like macrophages and FR-β expression.
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iNOS staining, on the contrary, showed a significantly higher per-
centage of positive cells in the slices with lowest accumulation of
99mTc-folate than with the highest accumulation (P 5 0.043).
However, staining of CD68 and CD86 was not significantly differ-
ent in slices with the highest accumulation of 99mTc-folate, com-
pared with slices with lowest accumulation (P 5 0.43 and 0.44,
respectively). Furthermore, CD163 colocalized with FR-b expres-
sion in a carotid plaque, as can be seen in a representative picture
(Fig. 3B).
Expression of Macrophage Markers by Flow Cytometry
To validate FR-b, CD86, and CD163 as macrophage subtype
markers, their expression on macrophage subpopulations was de-
termined using flow cytometry (representative examples in Fig. 4).
FR-b is expressed on 31% of M1-like macrophages and on 72% of
M2-like macrophages. In M1-like macrophages, 93% (60–97) of
cells were positive for CD86, whereas 34% (5–45) of cells were
positive for CD163. In contrast, M2-like
macrophages showed a high expression of
CD163 (86% [56–95]) whereas CD86 ex-
pression was lower (27% [10–40]), both
measured in 10 healthy volunteers.
In Vitro mRNA Expression of M1-Like
and M2-Like Markers
mRNA levels of GAPDH, IL-6, TNF,
TLR-2 and -4, FR-b, MR, IL-10, and
MMP-9 were determined in M1-like and
M2-like differentiated macrophages in du-
plicate from 6 healthy volunteers. The
mRNA expression of FR-b, MR, IL-10,
and MMP-9 was increased in M2-like mac-
rophages, compared with M1-like macro-
phages (P 5 0.09, 0.04, 0.06, and 0.004,
respectively, Fig. 5). On the contrary, TNF
and TLR-2 mRNA levels were significantly
higher in M1-like macrophages than in M2-
like macrophages (Fig. 6, P 5 0.002 for
both). No significant difference could be
found in mRNA levels of IL-6 and TLR-4
between M1-like and M2-like macrophages.
DISCUSSION
This is the first study, to our knowledge,
to show feasibility using 99mTc-folate to im-
age human atherosclerotic carotid plaques ex
vivo. Slices with the highest 99mTc-folate
accumulation showed significantly more
FR-b and CD163 expression, compared
with slices with the lowest 99mTc-folate ac-
cumulation, and significantly less expres-
sion of iNOS. Therefore, FR-b–positive
macrophages were found to be primarily
M2-like polarized macrophages, which
might be proatherogenic, due to production
of matrix-degrading enzymes.
Several research groups succeeded in
specifying macrophage subsets expressing
the folate receptor on tumor-associated M2
macrophages (16) and on M2 macrophages
expressed in experimental allergic asthma in mice (17). Further-
more, FR-b–targeted immunotoxin treatment resulted in the re-
duction of macrophages and plaque progression (18). However,
by our knowledge this is also the first study to show an over-
expression of FR-b on M2-like macrophages in atherosclerosis.
Nevertheless, identification of macrophage subtypes and determination
of their role in the atherosclerotic process is still a major challenge.
The M1 and M2 macrophage subtypes were observed in
atherosclerotic lesions previously (19,20). Shaikh et al. found
a higher proportion of M1 proinflammatory macrophages and a re-
duced proportion of M2 cells in symptomatic carotid lesions (21).
The discrepancy to our study could be due to the fact that the
former study compared the ratio of macrophage subtypes in the
carotid artery with those in vascular femoral plaques. In an exper-
imental atherosclerotic ApoE KO mice model, lesion progression
was correlated with the dominance of M1 (arginase [Arg] II1)
over the M2 (Arg I1) macrophage subtype (22). This result could
FIGURE 4. Representative flow cytometric analysis of M1-like and M2-like macrophage pop-
ulation from in vitro polarized macrophages, derived from peripheral blood mononuclear cells
from healthy control. (A) FR-β is expressed on 31% of M1-like macrophages and on 72% of M2-
like macrophages (red line). (B) CD86 is expressed on 93% of M1-like macrophages and on 27%
of M2-like macrophages (red line). (C) CD163 is expressed on 34% on M1-like macrophages and
on 86% of M2-like macrophages (red line). Isotypes in black in all graphs. APC = allophycocya-
nine; PE = phycoerythrin.
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be due to the proportion of M1 and M2 macrophages depending
on stadium of plaque formation in the ApoE model. In recent
published studies, other M2 markers were found to be related to
worse cardiovascular outcome (23–26). In sections derived from
subjects enrolled in the Cardiovascular Pathology Institute Sudden
Coronary Death Registry, stable plaques revealed few M2-like
macrophages (made visible by targeting the MR), compared with
unstable plaques in which the M2-like macrophage subpopulation
was abundant (23). Furthermore, patients with a 2.4-fold increased
cardiovascular risk, compared with patients with a low ratio, were
found to have a high MMP-12/CD68 ratio (24). MMP-12 was
found to be correlated with MMP-9–positive macrophage subpop-
ulations in a mouse model for obesity (25). Stöger et al. found
a correlation between areas of intraplaque hemorrhage and CD163
staining in human atherosclerosis. During development of plaques
both M1 and M2 cells accumulated, and the fibrous caps of
lesions showed no significant differences between subsets. In
contrast, vascular adventitial tissue displayed a pronounced M2
activation profile (26). These different studies support our hy-
pothesis that accumulation of M2-like macrophages might be
indicative of plaque vulnerability, which can be imaged by
99mTc-folate.
Folate receptors have been visualized be-
fore using optical fluorescent contrast agent
(FITC) labeled to folate by our group (7).
Other groups also used optical imaging for
the identification of tumor processes, as sev-
eral solid tumors express folate receptor-a,
demonstrated in ovarian cancer (27) and in
head and neck carcinoma expressing FR-b
(28). However, applications for noninvasive
optical imaging of fluorescent signals by the
use of fluorophores such as FITC could be
of less clinical value because of the limited
penetration depth of only a few millimeters.
This small penetration depth could be ex-
tended to a few centimeters using near-
infrared probes, but these are not ideal for
use in, for example, coronary arteries. 99mTc-
folate has a good tissue penetration and a rel-
atively short half-life. Furthermore, the
radiolabeling procedure for 99mTc-folate is
simple, and it has not shown toxicity or im-
munogenicity (8).
For in vivo folate receptor imaging, the
SPECT modality could be used; Ayala Lopez
et al. tested 99mTc-folate accumulation in ApoE KO mice on
a Western chow diet and showed a significantly greater accumu-
lation in atherosclerotic lesions than in mice on normal chow (8). In
humans, 111In-DTPA-folate and 99mTc-EC20-folate have been
tested in clinical trials as radiotracers for imaging of cancer
(FR-a) (29,30). Nevertheless, Winkel et al. showed that 111In-
EC0800 (a radiolabeled folate compound) detects plaque but
was not able to differentiate between a stable and a vulnerable
atherosclerotic carotid plaque in a shear stress-induced ApoE KO
mouse model (31). However, in this model macrophage content is
not different between the oscillatory shear stress region (stable
plaque) and the lowered shear stress region (vulnerable plaque)
(32). Also PET tracers have been developed recently, of which 39-
aza-29-18F-fluorofolic acid (33) has been shown to selectively tar-
get FR-b–positive macrophages in atherosclerotic plaques (34).
No determination of differential folate accumulation in the respec-
tive M1-like and M2-like subpopulation was performed in this
study. 18F-fluoro-polyethylene glycol-folate has been used in
a rat model of arthritis to image subclinical arthritis (35). For
imaging of plaque inflammation, 2-deoxy-2-18F-fluoro-D-mannose
has been developed recently, supporting a higher accumulation in
macrophages than 18F-FDG (23).
A limitation of our study is that division
of macrophages solely as M1 or M2 sub-
types may be too simple. As Wolfs et al.
suggest, the role of the local microenviron-
ment makes macrophage polarization in the
atherosclerotic tissue more complex than
the typically described M1 and M2 macro-
phages distribution (11). Thus, not only
cytokine environment but also foam cell
formation and CXCL4 (chemokine li-
gand 4, forming M4 macrophages), among
other factors, play major roles. The pres-
ence of other macrophages could explain
why a CD681 population in the plaque
does not stain for M1/M2 markers or FR-b
FIGURE 5. Relative expression of mRNA levels to GAPDH in 6 healthy volunteers. Quantitative
reverse-transcription polymerase chain reaction revealed higher relative expression in M2-like
macrophages (black dots) than M1-like macrophages (open dots) in FR-β (P 5 0.09) (A), MR (P 5
0.04) (B), IL-10 (P 5 0.06) (C), and MMP-9 (P 5 0.004) (D).
FIGURE 6. Relative expression of mRNA levels to GAPDH in 6 healthy volunteers measured in
duplo showing higher relative expression in M1-like macrophages (open dots) than M2-like mac-
rophages (black dots) in TNF (P 5 0.002) (A) and TLR-2 (P 5 0.002) (B).
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(Fig. 2A). Further studies to investigate the release of MMPs by
macrophage subtypes may give more insight. Also, because of the
inclusion of a low number of asymptomatic patients, no analyses
between the ratio of M1-like and M2-like macrophages in symp-
tomatic and asymptomatic disease could be made. More research
is necessary to explore this issue.
CONCLUSION
This is the first study showing a positive correlation between
accumulation of a 99mTc-folate compound in atherosclerotic plaques
and FR-b expression on M2-like macrophages. Furthermore,
we characterized macrophage phenotypes ex vivo and in vitro by
a panel of macrophage subtype markers. This characterization of
macrophage phenotypes not only enables the specific analysis of
the proportion of macrophage subtypes within a plaque, but also
opens ways to measure M2-like macrophage populations ex vivo.
More insight into macrophage subtypes and behavior in athero-
sclerotic plaques may give a better understanding of the pathogen-
esis related to the vulnerability of atherosclerotic plaques.
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